
Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of PMO (Phosphorodiamidate Morpholino Oligomers) Drug include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PMO (Phosphorodiamidate Morpholino Oligomers) Drug.
The PMO (Phosphorodiamidate Morpholino Oligomers) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Company
Avidity Biosciences
Dyne
Nippon Shinyaku
NS Pharma, Inc.
Sarepta Therapeutics, Inc
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type
DMD exon 45 Based
DMD exon 51 Based
DMD exon 53 Based
Other
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application
Hospital
Clinic
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of PMO (Phosphorodiamidate Morpholino Oligomers) Drug include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PMO (Phosphorodiamidate Morpholino Oligomers) Drug.
The PMO (Phosphorodiamidate Morpholino Oligomers) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Company
Avidity Biosciences
Dyne
Nippon Shinyaku
NS Pharma, Inc.
Sarepta Therapeutics, Inc
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type
DMD exon 45 Based
DMD exon 51 Based
DMD exon 53 Based
Other
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application
Hospital
Clinic
PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
88 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2020-2031)
- 1.4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2020-2025)
- 1.4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2026-2031)
- 1.5 Key Regions PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2020-2031)
- 1.5.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2020-2031)
- 1.5.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2020-2031)
- 1.5.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (2020-2031)
- 2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 DMD exon 45 Based
- 2.1.2 DMD exon 51 Based
- 2.1.3 DMD exon 53 Based
- 2.1.4 Other
- 2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
- 2.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Type (2020-2031)
- 2.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecasted by Type (2026-2031)
- 2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Regions
- 2.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Type (2020-2025)
- 3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
- 3.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Overview by Application (2020-2031)
- 3.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecasted by Application (2026-2031)
- 3.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Regions
- 3.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
- 4.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers
- 4.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges
- 4.4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2020-2025)
- 5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Company Headquarters & Area Served
- 5.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company, Product Type & Application
- 5.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Market Share by Revenue in 2024
- 5.6.3 2024 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Avidity Biosciences
- 6.1.1 Avidity Biosciences Comapny Information
- 6.1.2 Avidity Biosciences Business Overview
- 6.1.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- 6.1.5 Avidity Biosciences Recent Developments
- 6.2 Dyne
- 6.2.1 Dyne Comapny Information
- 6.2.2 Dyne Business Overview
- 6.2.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- 6.2.5 Dyne Recent Developments
- 6.3 Nippon Shinyaku
- 6.3.1 Nippon Shinyaku Comapny Information
- 6.3.2 Nippon Shinyaku Business Overview
- 6.3.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- 6.3.5 Nippon Shinyaku Recent Developments
- 6.4 NS Pharma, Inc.
- 6.4.1 NS Pharma, Inc. Comapny Information
- 6.4.2 NS Pharma, Inc. Business Overview
- 6.4.3 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- 6.4.5 NS Pharma, Inc. Recent Developments
- 6.5 Sarepta Therapeutics, Inc
- 6.5.1 Sarepta Therapeutics, Inc Comapny Information
- 6.5.2 Sarepta Therapeutics, Inc Business Overview
- 6.5.3 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- 6.5.5 Sarepta Therapeutics, Inc Recent Developments
- 7 North America
- 7.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2020-2025)
- 7.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2020-2025)
- 8.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2020-2025)
- 9.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2020-2025)
- 10.3 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2020-2025)
- 11.3 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.